8-K: Xilio Therapeutics Reports Strong 2025, Advances I-O Pipeline

Xilio Therapeutics announced its Q4 and full-year 2025 financial results, highlighting significant pipeline progress and an extended cash runway through 2027.

Summary

• Reported financial results for the fourth quarter and full year ended December 31, 2025.
• XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, is on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026.
• Advancing a potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1 with built-in co-stimulatory signaling.
• New preclinical data for the masked T cell engager program targeting CLDN18.2 will be presented at the AACR Annual Meeting from April 17-22, 2026.
• Extended cash runway through the end of 2027, excluding potential future milestone payments or contingent payments from collaborations and potential Series C warrant exercises.
• Achieved net income of $10.4 million for the fourth quarter of 2025, a significant improvement from a net loss of $13.1 million in the prior year period.
• Reduced full-year 2025 net loss to $35.0 million, down from $58.2 million in 2024.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by significant financial improvements, an extended cash runway, and consistent progress across a promising pipeline of masked immuno-oncology therapies.

Positives

• Achieved net income of $10.4 million for the fourth quarter ended December 31, 2025, compared to a net loss of $13.1 million for the same period in 2024.
• Reduced full-year 2025 net loss to $35.0 million, a substantial improvement from a $58.2 million net loss in 2024.
• Collaboration and license revenue significantly increased to $43.8 million for the full year 2025, up from $6.3 million in 2024, driven by agreements with AbbVie and Gilead.
• Cash and cash equivalents grew to $137.5 million as of December 31, 2025, compared to $55.3 million as of December 31, 2024.
• Extended cash runway through the end of 2027, providing financial stability for ongoing operations and pipeline advancement.
• XTX501, a bispecific PD-1 / masked IL-2, is progressing towards IND submission in mid-2026 and Phase 1 initiation in the second half of 2026.
• Advancing a potential first-in-class multi-specific, masked T cell engager targeting PSMA and STEAP1, addressing tumor heterogeneity and antigen escape in prostate cancer.
• New preclinical data for the CLDN18.2 masked T cell engager program will be presented at the AACR Annual Meeting, indicating continued scientific progress.
• Received $35.8 million in gross proceeds from the exercise of Series B warrants in January 2026.
• Closed a follow-on offering of prefunded warrants for $40.0 million in gross proceeds in February 2026, strengthening the cash position.
• Achieved a development milestone related to the masked antibody-based immunotherapy program under the collaboration with AbbVie in January 2026.

Negatives

• Despite significant improvements, the company still reported a net loss of $35.0 million for the full year ended December 31, 2025.
• Research & Development (R&D) expenses increased to $56.0 million for the full year 2025 from $41.2 million in 2024, reflecting increased development activities.
• General & Administrative (G&A) expenses increased to $29.7 million for the full year 2025 from $24.8 million in 2024, primarily due to professional and personnel-related costs.

Risks

• General market conditions and geopolitical uncertainties could impact operations and financial performance.
• Risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such studies or trials.
• Potential for delays in any current or planned preclinical studies or clinical trials or the development of product candidates.
• Ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates.
• Initial, preliminary, interim or retrospective preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results.
• Ability to successfully demonstrate the safety and efficacy of product candidates and gain regulatory approval on a timely basis, if at all.
• Results from preclinical studies or clinical trials for product candidates may not support further development.
• Actions of regulatory agencies may affect the initiation, timing and progress of current or future clinical trials.
• Ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates.
• Need to obtain additional cash resources to advance its pipeline of masked I-O molecules.
• Impact of international trade policies on business, including U.S. and China trade policies.
• Ability to maintain collaboration or partnership agreements with AbbVie, Gilead and Roche.

Future Outlook

Xilio plans to submit an IND application for XTX501 in mid-2026 and initiate a Phase 1 trial in the second half of 2026, with initial Phase 1 data expected in the second half of 2027. The company anticipates nominating a development candidate for its multi-specific, masked T cell engager targeting PSMA and STEAP1 in the second quarter of 2026. Furthermore, Xilio intends to advance its masked T cell engager programs into IND-enabling studies and submit IND applications for these programs in 2027. An option data package for efarindodekin alfa is expected to be delivered to Gilead in the first half of 2027. The company's existing cash and cash equivalents are projected to fund operations through the end of 2027.

Management Comments

• "As we enter 2026, we are well-positioned to leverage our clinically validated masking technology to continue advancing our next generation of multi-specific I-O therapies toward the clinic."
• "We are encouraged by the progress the field has recently made with masked T cell engagers for prostate cancer, and we are excited to be advancing a potential first-in-class multi-specific masked T cell engager targeting both PSMA and STEAP1 with built-in co-stimulatory signaling designed to enhance potency and durability of response."
• "We believe that targeting both PSMA and STEAP1, which are the most prevalent tumor-associated antigens expressed in prostate cancer, will minimize resistance due to antigen escape."
• "This quarter we continued to make strong progress advancing XTX501, our potential best-in-class bispecific PD-1 / masked IL-2, toward a planned IND submission mid-year."

Industry Context

StockSavvy.ai notes that Xilio's strategic focus on masked immuno-oncology therapies, including bispecific PD-1/IL-2 and multi-specific T cell engagers, aligns with a broader industry trend towards developing more targeted and tolerable cancer treatments. The emphasis on overcoming systemic side effects and addressing antigen escape in challenging cancers like prostate cancer positions Xilio within a highly competitive yet high-potential segment of the oncology market, where innovation in masking technology is crucial for differentiation and clinical success.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, extended cash runway, and pipeline advancements, potentially leading to increased investor confidence and share value.
• Employees: Continued employment and potential growth opportunities as the company's pipeline progresses and operations expand.
• Customers (Patients): Potential for new, more tolerable and effective cancer therapies in the future if ongoing clinical development is successful.
• Partners (AbbVie, Gilead): Continued collaboration and potential for future milestone payments based on program achievements.

Next Steps

• Submit an IND application for XTX501 in mid-2026.
• Initiate a Phase 1 trial for XTX501 in the second half of 2026.
• Report initial Phase 1 data for XTX501 in the second half of 2027.
• Present new preclinical data for the CLDN18.2 program at the AACR Annual Meeting (April 17-22, 2026).
• Nominate a development candidate for the PSMA and STEAP1 T cell engager program in the second quarter of 2026.
• Advance masked T cell engager programs into IND-enabling studies and submit IND applications in 2027.
• Deliver an option data package for efarindodekin alfa to Gilead Sciences, Inc. in the first half of 2027.

Key Dates

Recommendation

While Xilio Therapeutics demonstrates significant financial improvements, an extended cash runway, and promising pipeline progress in masked immuno-oncology, the company remains in a clinical-stage with substantial R&D expenses and a net loss for the full year. Future success is contingent on successful clinical trial outcomes and regulatory approvals, which carry inherent risks. The stock may be suitable for existing investors to hold given the positive momentum, but new investors might consider waiting for further de-risking through more advanced clinical data.

Keywords

immuno-oncology, cancer therapy, masked IL-2, T cell engager, bispecific, PD-1, PSMA, STEAP1, CLDN18.2, XTX501, efarindodekin alfa, biotechnology, clinical-stage, oncology, drug development, financial results